learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
Search
forLearn
3 / 3 resultslearn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
learn Stem Cell Factor
Research
5 / 1000+ results
research Toxicity Profile of Antibody-Drug Conjugates in Breast Cancer: Practical Considerations
ADCs can effectively treat breast cancer but may cause side effects like nausea and hair loss.
research Antibody Drug Conjugates
Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.
research Antibody-Drug Conjugate Induced Hair Loss Responds to Minoxidil: A Case Report
Oral minoxidil can help regrow hair lost from antibody-drug conjugate treatment.
research Targeting Integrin Pathways: Mechanisms and Advances in Therapy
New therapies are being developed that target integrin pathways to treat various diseases.
research Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
Adding a second method to PROTACs could improve cancer treatment.
Community Join
5 / 49 resultscommunity Why hasn’t anyone made a "DHT sponge" biologic yet???
The conversation discusses the potential for developing a biologic "DHT sponge" to neutralize DHT in the bloodstream as a treatment for hair loss, suggesting it could be more targeted and have fewer side effects than current treatments like finasteride and dutasteride. Concerns include the complexity, cost, and potential side effects of such a treatment, as well as skepticism about its feasibility and market interest.
community Testosterone and hair loss seeming irrelevance
The conversation is about the role of testosterone in hair loss and the effectiveness of different treatments. The conclusion is that DHT is the main culprit for hair loss, and finasteride has been proven to work long-term in maintaining and regrowing hair. Testosterone may have a minor effect, but it is not the primary cause of hair loss.
community HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
community HMI-115 question about potential earliest access
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.
community All Drugs in Clinical Trials in 2023
12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.